Telix Completes BiPASS Enrollment and Secures FDA NDA Pathway for Prostate Cancer Imaging Agent

Telix has successfully completed the enrollment of 350 patients in its BiPASS study and has reached an agreement with the FDA on a New Drug Application (NDA) pathway for 68Ga-PSMA-PET, an imaging agent intended for use in pre-biopsy prostate cancer imaging.